Therapy area
Multiple sclerosis
ATC groups L04AA, L03AB, L04AG
- Molecules
- 32
- Current shortages
- 0
Disease-modifying therapies for relapsing and progressive multiple sclerosis.
Molecules
32 molecules, most requested first.
- MycophenolateAntimetabolite Immunosuppressant13 presentations7 brandsL04AA06
- EverolimusOrphanKinase Inhibitor30 presentations7 brandsL01XE10
- CladribinePurine Antimetabolite4 presentations3 brandsL01BB04
- Interferon beta-1aOrphanInterferon beta9 presentations6 brandsL03AB07
- EmapalumabOrphanInterferon gamma Blocker7 presentations1 brandL04AG09
- ApremilastOrphanPhosphodiesterase 4 Inhibitor5 presentations3 brandsL04AA32
- Peginterferon beta-1aBiologicInterferon beta5 presentations3 brandsL03AB13
- AbataceptOrphanSelective T Cell Costimulation Modulator4 presentations2 brandsL04AA24
- UpadacitinibOrphanJanus Kinase Inhibitor4 presentations2 brandsL04AA44
- OzanimodSphingosine 1-phosphate Receptor Modulator3 presentations4 brandsL04AA38
- BelimumabBiologicB Lymphocyte Stimulator-specific Inhibitor2 presentations2 brandsL04AG04
- VedolizumabBiologicIntegrin Receptor Antagonist3 presentations3 brandsL04AA33
- AlemtuzumabOrphanCD52-directed Cytolytic Antibody2 presentations3 brandsL01XC04
- AnifrolumabBiologicType I Interferon Receptor Antagonist2 presentations2 brandsL04AG11
- Interferon beta-1bOrphan1 presentation2 brandsL03AB08
- Mycophenolic acidAntimetabolite Immunosuppressant2 presentationsL04AA06
- NatalizumabBiologicIntegrin Receptor Antagonist2 presentations3 brandsL03AD
- NerandomilastOrphan2 presentations2 brandsL04AA61
- Peginterferon alfa-2aBiologicInterferon alpha2 presentations1 brandL03AB11
- RavulizumabOrphanComplement Inhibitor2 presentations2 brandsL04AA43
- Ropeginterferon alfa-2bOrphanInterferon alfa-2b2 presentations3 brandsL03AB15
- BelataceptOrphanSelective T Cell Costimulation Blocker1 presentation2 brandsL04AA28
- BelumosudilOrphan1 presentation2 brandsL04AA48
- Efgartigimod alfaOrphanNeonatal Fc Receptor Blocker1 presentation1 brandL04AA58
- InebilizumabOrphanCD19-directed Cytolytic Antibody1 presentation2 brandsL04AA
- Interferon gamma-1bOrphanInterferon gamma1 presentation1 brandL03AB03
- OcrelizumabBiologicAntibodies1 presentation2 brandsL04AG08
- OfatumumabOrphanCD20-directed Cytolytic Antibody1 presentation2 brandsL01FA02
- RemibrutinibKinase Inhibitor1 presentation2 brandsL04AA60
- TeprotumumabOrphanInsulin-like Growth Factor-1 Receptor Inhibitor1 presentation2 brandsL04AG13
- ImlifidaseOrphan1 brandL04AA
- Tolebrutinib1 brandL04AA62
Conditions
Country notes
Import rules differ by country, for example permits for unregistered medicines or named-patient routes. Each country guide explains who applies, the documents needed and typical timelines.
All import guidesFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Sourcing Multiple sclerosis medicines?
Add the molecules you need to one request. We check each country's import rules before we quote.